Neuroprotectant for Hypertensive Intracerebral Hemorrhage

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 422 participants.

Also called NCT03546283

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 422 participants (planned count) (from the registry)
Sponsor
Rong Hu, MD (from the registry)
Registry
  • NCT NCT03546283
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03546283. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-15 (anticipated); primary completion 2020-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Neuroprotectant for Hypertensive Intracerebral Hemorrhage
Condition
Intracerebral Hemorrhage
Intervention (Drug)
Placebos
Intervention (Drug)
Cattle Encephalon Glycoside and Ignotin
Lead sponsor
Rong Hu, MD (class: other)

Record details

Record id
cardio:ct-nct03546283
Content hash
763b9da1b7f284a0ffd6a83c62c5020482fd6b6e2b093873a5e5a3249589caef